Bristol Myers Squibb and Eisai forged a strategic collaboration that could be worth nearly $2.5 billion to jointly develop MORAb-202, an antibody drug conjugate (ADC) to be used against certain solid tumors across several different cancer types.

Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.  

2021 is shaping up to be another banner year for biotech companies. According to BioSpace, funds appear to be in near-endless supply as companies advance next-gen technologies and therapeutics for the health of all. BioSpace reviews a few raking in cash for their programs.

An investigational Alzheimer’s disease (AD) drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.

Takeda Pharmaceutical is advancing the Japanese pharma giant’s immune-oncology portfolio through the acquisition of the immunotherapy pioneer Maverick Therapeutics.

A Phase III trial of NurOwn (MSC-NTF cells), BrainStorm Cell Therapeutics’ investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the product and placebo for improving scores on a revised ALS functional rating scale (ALSFRS-R) that measures the severity of the disease.

Preclinical data for Pfizer and BioNTech’s Phase II/III Covid-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge, the two companies announced.

Arcturus Therapeutics Holdings Inc. said the first group of participants were dosed in an early-stage trial testing the company’s Covid-19 vaccine candidate and that results from the trial were expected in fourth-quarter 2020.

Johnson & Johnson’s Janssen Pharmaceutical Companies entered into an agreement with the U.S. government for the large-scale domestic manufacturing and delivery in the United States of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use following approval or Emergency Use Authorization by the Food and Drug Administration.

San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of the company’s lead breast cancer treatment as well as expand ongoing research and development programs.